Article
Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism.
The pharmacogenomics journal - 1 Jan 2005
Tiwari A K, Deshpande S N, Rao A R, Bhatia T, Mukit S R, Shriharsh V, Lerer B, Nimagaonkar V L, Thelma B K
Abstract excerpt
Understanding the pharmacogenetic basis of developing iatrogenic disorders such as Tardive Dyskinesia (TD) has significant clinical implications. CYP1A2, an inducible gene of the cytochrome P450 family of genes, has been suggested to contribute to the metabolism of typical antipsychotics in subjects with schizophrenia on long-term treatment, and has been considered as a potential candidate gene for development of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.